Inspira™ Technologies Reveals Next Generation Liby™ System, an Extracorporeal Membrane Oxygenation System, Targeting a $531 Million Global ECMO Market
Retrieved on:
Monday, July 11, 2022
Intubation, Human, FDA, National Association Medical Staff Services, Regulation of tobacco by the U.S. Food and Drug Administration, ART, Unitary state, OXY, Intensive care unit, Risk, Coma, Form 20-F, Annual report, Transport, Food, Ambulance, Company, Carbon, Health, Mauro Libi Crestani, U.S. Securities and Exchange Commission, Nasdaq, Extracorporeal membrane oxygenation, Technology, Time, ECMO, Proton Inspira, Patient, SEC, Hospital, High-dependency unit, Medical device
The Liby System is intended to target the $531million global ECMO market.
Key Points:
- The Liby System is intended to target the $531million global ECMO market.
- The Inspira Technologies Liby system currently under development, is expected to be submitted to the U.S. Food and Drug Administration (FDA) for approval, during the first half of 2023.
- The Inspira Technologies Liby system is designed to be a new generation ECMO system, with potential advantages that may improve usability and patient care.
- Dagi Ben-Noon, Inspira Technologies' Chief Executive Officer, stated:
"The Liby system is intended to target one of three market segments within Inspira Technologies product scope.